Back to rankings

KIMBERLY-CLARK CORP (KMB)

Fair Value
Consumer DefensiveHousehold & Personal ProductsUnited States

Fundamental

59

Price

$97.43

Market Cap

$32.27B

Part 1 · What the company is worth

Overview

Kimberly-Clark makes disposable personal-care and tissue products — diapers (Huggies), feminine and adult care, paper towels and toilet paper (Kleenex, Scott) — sold mainly through supermarkets, mass retailers and pharmacies. Its North America business is the larger and more profitable half; a separate International Personal Care unit sells largely the same categories outside the US and Canada. It is also folding in Kenvue (Tylenol, Band-Aid, Listerine) through a pending acquisition, and moving its non-US tissue business into a joint venture with Brazil's Suzano.

How it makes money

Kimberly-Clark sells everyday disposable products that customers repurchase every few weeks, so revenue depends on volume and price/mix rather than one-time big-ticket sales. It negotiates directly with a small number of very large retailers — Walmart alone is about 16% of net sales — who control shelf space and can push back hard on price increases, especially when store-brand alternatives sit right next to Kimberly-Clark's products. Profitability rises and falls largely with the cost of pulp, resin and other raw materials relative to what retailers accept in price increases.

Revenue by segment

North America65.85%

Personal care and tissue brands sold in the US and Canada, Kimberly-Clark's largest and most profitable market.

International Personal Care34.15%

Diapers, feminine and adult care products sold outside North America, largely in emerging markets.

Competitive moat

Brand · Narrow

Huggies, Kleenex and Scott are recognized household names that let Kimberly-Clark charge more than unbranded alternatives and secure shelf space with retailers. But private-label products sit right next to them at lower prices in every category it competes in, and large retailers hold real bargaining power over listing and price, so the brand premium is real but limited rather than dominant.

What drives demand

Defensive

Diapers, tissue and paper towels are bought regardless of the economic cycle, since consumers rarely cut back on basic hygiene products even in a downturn, which keeps volumes fairly stable. The bigger swing factor is the input-cost cycle — pulp, resin and energy prices — and retailers' willingness to accept the price increases needed to offset it, not end-consumer demand itself.

Key risks

  • Retailer bargaining power — A handful of very large retailers, led by Walmart, control the shelf space Kimberly-Clark depends on and can resist price increases or favor private-label alternatives.
  • Raw material cost volatility — Prices for pulp, resin, energy and other key inputs can rise sharply, and Kimberly-Clark may not be able to fully offset them through pricing without hurting volume.
  • Kenvue acquisition integration — The pending Kenvue acquisition will substantially increase debt and carries execution risk; the deal could also be delayed, face regulatory obstacles, or fail to deliver the expected synergies.
  • Private-label competition — Store-brand competitors, some with significantly lower development and manufacturing costs, offer comparable products at lower prices in nearly every category Kimberly-Clark serves.

Customer concentration

Top customers account for 16% of revenue

Walmart alone accounted for approximately 16% of net sales from continuing operations in 2025, concentrated mostly in the North America segment; losing shelf space or favorable terms with a retailer this size would be difficult to replace elsewhere.

The case for

Buyers argue that Kleenex, Huggies and Scott are habitual purchases that hold their shelf position through economic cycles, that adding Kenvue's health-care brands diversifies the business beyond paper and diaper categories, and that shedding the lower-margin international tissue business into the Suzano joint venture should lift overall margins.

The case against

Sellers worry that the Kenvue deal loads the balance sheet with new debt right as Kimberly-Clark still has to prove the acquisition's synergies, that a handful of retailers led by Walmart can squeeze pricing whenever input costs rise, and that private-label alternatives keep gaining share in categories where the brand premium is hardest to defend.

Written by the editors, published on August 18, 2026

Direct competitors

Who this company fights with for the same customers

Compare

Generated on September 19, 2026 with claude-haiku-4-5 — shared with all users

P/E: 21.9Score: 60Market cap: $346.41B

P&G goes head to head with Kimberly-Clark on supermarket shelves worldwide in disposable diapers (Pampers vs Huggies), feminine care (Always vs Kotex) and paper towels and toilet tissue (Bounty and Charmin vs Scott and Cottonelle).

Essity ABNot tracked

The Swedish hygiene group names Kimberly-Clark as a direct competitor in both personal care and tissue, and the two fight for the same customers in adult incontinence (TENA vs Depend) and in away-from-home washroom supplies sold to offices and hospitals (Tork vs Kimberly-Clark Professional).

Unicharm Corporation (ユニ・チャーム株式会社)Not tracked

Unicharm is the leading maker of baby diapers, feminine care and adult incontinence products across Japan, China and Southeast Asia, the same categories and the same fast-growing Asian consumers Kimberly-Clark targets with Huggies and Kotex.

Georgia-Pacific LLCNot tracked

Privately held by Koch Industries, Georgia-Pacific sells Angel Soft, Quilted Northern and Brawny in US supermarkets and Dixie and enMotion washroom systems to businesses, competing directly with Scott, Cottonelle and Kimberly-Clark Professional.

Ontex Group NVNot tracked

Ontex is one of the largest makers of private-label diapers, feminine pads and incontinence products for European and American retailers, the store-brand pressure Kimberly-Clark's 10-K singles out as a threat to its branded volumes.

Balance Sheet & Liquidity

Revenue

$16.58B

Trailing 12 months (through 6/30/2026)

Net Income

$1.96B

Trailing 12 months (through 6/30/2026)

Free Cash Flow

$1.64B

Total Equity

$1.50B

Total Liabilities

$15.47B

Current Ratio

0.91

Interest Coverage

9.18

Debt/EBITDA

2.06

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseFairly Valued

Fair Value

$102.73

Current Price

$97.43

Margin of Safety

+5.2%

Fair Value Range

$66.78 - $138.69

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$116.33
Discounted cash flow (DCF):$151.08
Earnings multiple (P/E):$67.30
Graham growth formula:$37.85
Earnings power value (EPV):$74.48
Justified P/B:$134.15
Dividend discount (Gordon):$130.06
P/FFO, funds from operations:$135.96
Mid-cycle earnings:$117.10
Revenue multiple:$58.94
Analyst Consensus:Buy (10B / 10H / 1S)
Last Earnings Surprise:+4.20%

Valuation Metrics

P/E Ratio

16.57

ROE

134.6%

P/B Ratio

18.52

P/FCF

17.80

Gross Margin

36.8%

ROIC

18.6%

Profitability Radar

Value Creation (Economic Moat)

ROIC

18.6%

WACC

7.2%

ROIC − WACC

+11.4 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Fundamental Analysis Criteria

Passed (15)

  • EPS shows upward trend
  • ROIC 18.6%
  • Gross Margin 36.8%
  • P/FCF 17.80
  • Operating Margin 14.3%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 122.6%
  • Earnings Surprise avg 2.9%
  • Earnings Quality (OCF/NI) 1.70
  • Share Dilution -1.2%
  • Piotroski F-Score 5/9

Failed (11)

  • EPS CAGR 2.23%
  • Price CAGR -1.54%
  • P/B Ratio 18.52
  • Debt/Equity ratio
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • Revenue Growth 5Y -3.0%
  • Analyst Consensus 48% Buy
  • Net Margin Trend 11.8% vs 14.8%

Unavailable (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

5/9

Mixed signals: some areas need attention

score
criteria

Earnings Quality

1.70

High quality: earnings backed by cash

Share Dilution

-1.2%

Buying back shares. Shareholder friendly

Institutional Holdings

Governance

Executive Team

NameTitleAge
Mr. Michael D. HsuChairman & CEO61
Mr. Russell C. TorresPresident & COO53
Mr. Nelson UrdanetaSenior VP, CFO & Interim Principal Accounting Officer,53
Mr. Jeffrey P. Melucci J.D.Chief Strategy, Business Development & Administrative Officer54
Mr. Francesco TintoChief Information & Global Business Services Officer-
Mr. Christopher M. Jakubik C.F.A.Investor Relations Contact-
Ms. Suzana BladesSenior VP & General Counsel-
Ms. Preeti BinoyHead Corporate Communications & Government Affairs - India-
Ms. Stacey J. Valy PanayiotouChief Human Resources Officer52
Mr. Ehab Abou-OafChief Executive Officer of Arbex58

Audit Risk

3

Board Risk

5

Compensation Risk

6

Shareholder Rights Risk

4

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-12

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-08-04

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-09-28

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Latest News

Recent headlines for KMB, sourced from Markets Gazette.

No recent news for KMB.